CD274 and endometrial cancer: A series of studies have explored the prognostic and therapeutic value of programmed death-1(PD-1)/ programmed death-ligand 1 (PD-L1) in patients with endometrial cancer (EC); however, the effect of them are controversial, such as Pembrolizumab, an antibody targeting PD-1, which just has moderate efficacy 42.